中和抗体
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2024/03/21 15:14 UTC 版)
中和抗体(ちゅうわこうたい、英: neutralizing antibody, NAb)は、病原体や感染性粒子が細胞に対して及ぼす生物学的な影響を中和して、細胞を防御する抗体である。中和によって病原体や感染性粒子は感染性や病原性を失う[3]。中和抗体は、ウイルス、細胞内細菌、微生物毒素に対する適応免疫系の体液性応答の一部である。中和抗体は、感染性粒子の表面構造(抗原)に特異的に結合することで、宿主細胞が感染して破壊する可能性のある相互作用を防ぐ。中和抗体による免疫は、感染が起こる前に免疫系が感染粒子を排除するため、殺菌免疫(英: sterilizing immunity)としても知られている[4]。
- ^ Mike Recher; Karl S Lang; Lukas Hunziker; Stefan Freigang; Bruno Eschli; Nicola L Harris; Alexander Navarini; Beatrice M Senn et al. (8 August 2004). “Deliberate removal of T cell help improves virus-neutralizing antibody production”. Nature Immunology 5 (9): 934–942. doi:10.1038/ni1102. PMID 15300247 .
- ^ a b Stachowiak (2008年8月15日). “Neutralizing Antibodies and Disease-Modifying Therapies for Multiple Sclerosis”. About.com. 2009年6月13日閲覧。
- ^ “Neutralising antibody”. Biology-Online (2008年). 2009年7月4日閲覧。
- ^ Dutta, A; Huang, CT; Lin, CY; Chen, TC; Lin, YC; Chang, CS; He, YC (6 September 2016). “Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs.”. Scientific Reports 6: 32973. Bibcode: 2016NatSR...632973D. doi:10.1038/srep32973. PMC 5011745. PMID 27596047 .
- ^ Principles of Virology, Volume 1: Molecular Biology (4th ed.). ASM Press. (2015). p. 31. ISBN 978-1555819330
- ^ Principles of Virology, Volume 2: Pathogenesis and Control (4th ed.). ASM Press. (2015). p. 125. ISBN 978-1-555-81951-4
- ^ Treffers, Henry P. (2014). “Neutralizing antibody”. AccessScience (McGraw-Hill). doi:10.1036/1097-8542.450600 .
- ^ Janeway's immunobiology (8th ed.). Garland Science. (2012). p. 388. ISBN 978-0-8153-4243-4
- ^ Schmaljohn, AL (July 2013). “Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts.”. Current HIV Research 11 (5): 345–53. doi:10.2174/1570162x113116660057. PMID 24191933.
- ^ Tirado, SM; Yoon, KJ (2003). “Antibody-dependent enhancement of virus infection and disease.”. Viral Immunology 16 (1): 69–86. doi:10.1089/088282403763635465. PMID 12725690.
- ^ Dejnirattisai, Wanwisa; Supasa, Piyada; Wongwiwat, Wiyada; Rouvinski, Alexander; Barba-Spaeth, Giovanna; Duangchinda, Thaneeya; Sakuntabhai, Anavaj; Cao-Lormeau, Van-Mai et al. (23 June 2016). “Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus”. Nature Immunology 17 (9): 1102–1108. doi:10.1038/ni.3515. PMC 4994874. PMID 27339099 .
- ^ Jung, David; Alt, Frederick W (January 2004). “Unraveling V(D)J Recombination”. Cell 116 (2): 299–311. doi:10.1016/S0092-8674(04)00039-X. PMID 14744439.
- ^ a b Janeway's immunobiology (8th ed.). Garland Science. (2012). pp. 389–404. ISBN 978-0-8153-4243-4
- ^ a b VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (2016). “Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity” (英語). Microbiology and Molecular Biology Reviews 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. ISSN 1092-2172. PMC 5116878. PMID 27784796 .
- ^ Crispin, Max; Ward, Andrew B.; Wilson, Ian A. (2018-05-20). “Structure and Immune Recognition of the HIV Glycan Shield” (英語). Annual Review of Biophysics 47 (1): 499–523. doi:10.1146/annurev-biophys-060414-034156. ISSN 1936-122X. PMC 6163090. PMID 29595997 .
- ^ Guha, Debjani; Ayyavoo, Velpandi (2013). “Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1” (英語). ISRN AIDS 2013: 954806. doi:10.1155/2013/954806. ISSN 2090-939X. PMC 3767209. PMID 24052891 .
- ^ a b Salazar, Georgina; Zhang, Ningyan; Fu, Tong-Ming; An, Zhiqiang (10 July 2017). “Antibody therapies for the prevention and treatment of viral infections”. NPJ Vaccines 2 (1): 19. doi:10.1038/s41541-017-0019-3. PMC 5627241. PMID 29263875 .
- ^ a b Casadevall, A; Dadachova, E; Pirofski, LA (September 2004). “Passive antibody therapy for infectious diseases.”. Nature Reviews. Microbiology 2 (9): 695–703. doi:10.1038/nrmicro974. PMID 15372080.
- ^ Kreil, Thomas R. (March 2015). “Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors”. Emerging Infectious Diseases 21 (3): 521–523. doi:10.3201/eid2103.141838. PMID 25695274.
- ^ Schmidt, Rebecca; Beltzig, Lea C.; Sawatsky, Bevan; Dolnik, Olga; Dietzel, Erik; Krähling, Verena; Volz, Asisa; Sutter, Gerd et al. (5 October 2018). “Generation of therapeutic antisera for emerging viral infections”. NPJ Vaccines 3 (1). doi:10.1038/s41541-018-0082-4. PMID 30323953.
- ^ Hung, I. F.; To, K. K.; Lee, C.-K.; Lee, K.-L.; Chan, K.; Yan, W.-W.; Liu, R.; Watt, C.-L. et al. (19 January 2011). “Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection”. Clinical Infectious Diseases 52 (4): 447–456. doi:10.1093/cid/ciq106. PMID 21248066.
- ^ World Health Organization. “WHO | Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease”. WHO. 2020年4月5日閲覧。
- ^ Shen, Chenguang; Wang, Zhaoqin; Zhao, Fang; Yang, Yang; Li, Jinxiu; Yuan, Jing; Wang, Fuxiang; Li, Delin et al. (27 March 2020). “Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma”. JAMA 323 (16): 1582. doi:10.1001/jama.2020.4783. PMC 7101507. PMID 32219428 .
- ^ Casadevall, Arturo; Pirofski, Liise-anne (13 March 2020). “The convalescent sera option for containing COVID-19”. Journal of Clinical Investigation 130 (4): 1545–1548. doi:10.1172/JCI138003. PMID 32167489.
- ^ Bregenholt, S; Jensen, A; Lantto, J; Hyldig, S; Haurum, JS (2006). “Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.”. Current Pharmaceutical Design 12 (16): 2007–15. doi:10.2174/138161206777442173. PMID 16787244.
- ^ “Our Formulary”. Infectious Diseases Laboratories. Centers for Disease Control and Prevention. 2016年12月16日時点のオリジナルよりアーカイブ。2016年12月9日閲覧。
- ^ “A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection”. New England Journal of Medicine 375 (15): 1448–1456. (13 October 2016). doi:10.1056/NEJMoa1604330. PMC 5086427. PMID 27732819 .
- ^ “Label - Palivizumab (Synagis), Medimmune, Incorporated”. 2020年2月4日閲覧。
- ^ VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (26 October 2016). “Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity”. Microbiology and Molecular Biology Reviews 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. PMID 27784796.
- ^ Kwong, P. D.; Mascola, J. R.; Nabel, G. J. (1 September 2011). “Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1”. Cold Spring Harbor Perspectives in Medicine 1 (1): a007278. doi:10.1101/cshperspect.a007278. PMID 22229123.
- ^ Burton, Dennis R. (2002). “Antibodies, viruses and vaccines” (英語). Nature Reviews Immunology 2 (9): 706–713. doi:10.1038/nri891. ISSN 1474-1733. PMID 12209139.
- ^ Kaslow, R. A., ed (2014). Viral Infections of Humans: Epidemiology and Control (5th ed.). Springer. p. 56. ISBN 9781489974488 2020年4月4日閲覧。
- ^ Santoro, MM; Perno, CF (2013). “HIV-1 Genetic Variability and Clinical Implications.”. ISRN Microbiology 2013: 481314. doi:10.1155/2013/481314. PMC 3703378. PMID 23844315 .
- ^ a b Kumar, R; Qureshi, H; Deshpande, S; Bhattacharya, J (August 2018). “Broadly neutralizing antibodies in HIV-1 treatment and prevention.”. Therapeutic Advances in Vaccines and Immunotherapy 6 (4): 61–68. doi:10.1177/2515135518800689. PMC 6187420. PMID 30345419 .
- ^ Cohen, J. (2013). “Bound for Glory”. Science 341 (6151): 1168–1171. Bibcode: 2013Sci...341.1168C. doi:10.1126/science.341.6151.1168. PMID 24030996.
- ^ Simek, MD; Rida, W; Priddy, FH; Pung, P; Carrow, E; Laufer, DS; Lehrman, JK; Boaz, M et al. (July 2009). “Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.”. Journal of Virology 83 (14): 7337–48. doi:10.1128/JVI.00110-09. PMC 2704778. PMID 19439467 .
- ^ Haynes, Barton F.; Burton, Dennis R.; Mascola, John R. (30 October 2019). “Multiple roles for HIV broadly neutralizing antibodies”. Science Translational Medicine 11 (516): eaaz2686. doi:10.1126/scitranslmed.aaz2686. PMC 7171597. PMID 31666399 .
- ^ “HIV Databases”. Los Alamos National Laboratory. 2021年1月12日閲覧。
- ^ Corti, D; Cameroni, E; Guarino, B; Kallewaard, NL; Zhu, Q; Lanzavecchia, A (June 2017). “Tackling influenza with broadly neutralizing antibodies.”. Current Opinion in Virology 24: 60–69. doi:10.1016/j.coviro.2017.03.002. PMC 7102826. PMID 28527859 .
- ^ Colbert, MD; Flyak, AI; Ogega, CO; Kinchen, VJ; Massaccesi, G; Hernandez, M; Davidson, E; Doranz, BJ et al. (15 July 2019). “Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.”. Journal of Virology 93 (14). doi:10.1128/JVI.02070-18. PMC 6600205. PMID 31068427 .
- ^ Durham, ND; Agrawal, A; Waltari, E; Croote, D; Zanini, F; Fouch, M; Davidson, E; Smith, O et al. (10 December 2019). “Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics.”. eLife 8. doi:10.7554/eLife.52384. PMC 6927745. PMID 31820734 .
- ^ Goo, L; Debbink, K; Kose, N; Sapparapu, G; Doyle, MP; Wessel, AW; Richner, JM; Burgomaster, KE et al. (January 2019). “A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.”. Nature Microbiology 4 (1): 71–77. doi:10.1038/s41564-018-0283-7. PMC 6435290. PMID 30455471 .
- ^ Bhiman, Jinal N.; Lynch, Rebecca M. (2017-03-27). “Broadly neutralizing antibodies as treatment: effects on virus and immune system”. Current HIV/AIDS Reports 14 (2): 54–62. doi:10.1007/s11904-017-0352-1. ISSN 1548-3568. PMC 5401706. PMID 28349376 .
- 1 中和抗体とは
- 2 中和抗体の概要
- 3 ウイルスの中和抗体回避
- 4 脚注
中和抗体と同じ種類の言葉
- 中和抗体のページへのリンク